50 filings analyzed. Top movers: Hyperscale Data, Inc., Boxlight Corp, Fly-E Group, Inc., NextCure, Inc., GoPro, Inc..
SCHEDULE 13D
Hyperscale Data, Inc.
On August 6, 2026, Ault Lending LLC agreed to purchase 470,172 Class C Ordinary Shares (post-reverse split) from Target Capital 12 LLC ($5.59M), Secure Net Capital LLC ($4.05M), and Great Point Capital LLC ($2.07M) for a total of $11.71M. The deal eliminates board/management rights previously granted to sellers under an original January 2026 Securities Purchase Agreement. Ault Lending separately converted 776,466 Class C shares to Class A and sold/bought shares in open market trading during Sept–Nov 2026; Milton C. Ault III personally bought/sold smaller quantities. The transaction reflects existing insiders (Ault-controlled entities) consolidating equity after other investors liquidate positions.
▼ Likely negative
· significance 97 · Ownership Agent
S-1/A
Boxlight Corp
Boxlight Corporation (Nevada, public market cap ~$4.5M) filed Amendment No. 2 to its Form S-1 registration statement on November 10, 2026, registering resale of up to 47.5 million shares of Class A Common Stock. The shares comprise: (i) 30.4M shares convertible from 937,500 Series D Preferred shares (issued August 5, 2026 private placement, amended September 30, 2026); (ii) 15.2M shares from Secure Net Capital LLC equity purchase agreement (August 5, 2026, $15M commitment over 36 months); and (iii) 1.78M shares from J.J. Astor inventory finance agreement (May 27, 2025, amended April 1, 2026). The filing is exhibit-only (no business changes disclosed in amendment itself); Lucosky Brookman LLP opines the issued and issuable shares will be validly issued and fully paid.
▼ Likely negative
· significance 92 · Registration Agent
S-1
Fly-E Group, Inc.
Fly-E Group, Inc., a $20.2M-market-cap EV micro-mobility company, filed a Form S-1 on November 9, 2026 to raise approximately $9.0M gross proceeds via a best-efforts offering of common stock, pre-funded warrants (exercise price $0.0001), and regular warrants (zero exercise price option available). The offering is unregistered, has no minimum, no escrow, and 7% placement agent fees ($630K max). Univest Securities, LLC is the sole placement agent. Major risks: (1) company faces going-concern doubt with only $60K cash as of June 30, 2026; (2) three pending lawsuits (securities class action, consolidated derivative suits, $3.94M Peapack bank loan default); (3) SEC investigation initiated January 2026; (4) material weaknesses in internal controls; (5) $5M credit facility in default since August 2025 with forbearance expired June 30, 2026. Warrants carry zero exercise price, creating unlimited dilution with no proceeds to company.
▼ Likely negative
· significance 92 · Registration Agent
8-K
NextCure, Inc.
NextCure is advancing its proposed merger with Avere Therapeutics, which is now supported by approximately $820 million in committed financing ($320M concurrent private placement + $500M additional private placement, with ~$266M satisfied via contribution/cancellation of Avere convertible notes). The SEC declared the S-4 registration statement effective on November 6, 2026, with stockholders scheduled to vote on December 9, 2026. NextCure simultaneously completed major restructuring—workforce reductions, facility lease terminations, asset sales—and transitioned the LNCB74 program to LigaChem while retaining milestone and royalty rights.
▲ Likely positive
· significance 92 · 8-K Agent
8-K
GoPro, Inc.
GoPro filed a Form 12b-25 on November 10, 2026, notifying the SEC it cannot file its Q3 2026 10-Q on time due to unresolved accounting for financing arrangements and a material weakness in internal controls over financial reporting that remains unmediated. The company disclosed Q3 2026 preliminary results: revenue ~$96M (vs. $163M YoY, -41%), gross margin ~12.7% (vs. 35.1% YoY, -2,240 bps), and operating expenses ~$60M (vs. $73M YoY). Additionally, GoPro is seeking waivers from lenders on covenant noncompliance; failure to obtain waivers could trigger default, acceleration of debt, and termination of a pending merger agreement. The financial statements will continue to reflect substantial doubt about going-concern status.
▼ Likely negative
· significance 92 · 8-K Agent
S-11
Wheeler Real Estate Investment Trust, Inc.
Wheeler Real Estate Investment Trust filed Form S-11 on November 10, 2026, registering up to 100,002,030 shares of common stock issuable upon redemption of Series D Cumulative Convertible Preferred Stock. Series D holders may redeem at $25/share plus accrued dividends, paid in common stock at volume-weighted average price (VWAP) of preceding 10 trading days (currently $0.61/share as of filing). Company expects first redemption on December 7, 2026; will receive no proceeds from issuance. Filing also covers 2,030 previously registered shares under prior Form S-11.
▼ Likely negative
· significance 92 · Registration Agent
8-K
Rent the Runway, Inc.
On November 4, 2026, Rent the Runway received a notice of delisting or failure to satisfy continued listing standards. The filing indicates Item 3.01 (Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing) was triggered, though the specific listing rule violated and remediation timeline are not detailed in the document index provided.
▼ Likely negative
· significance 92 · 8-K Agent
F-1MEF
TOP SHIPS INC.
TOP SHIPS INC. filed an F-1MEF registration statement on November 10, 2026, to register an additional 45,000,000 common shares (post-reverse stock split effective November 6, 2026) for sale by B. Riley Principal Capital II, LLC under a Common Shares Purchase Agreement dated April 24, 2026. Total registered securities now reach 50,000,000 common shares with preferred stock purchase rights; no additional filing fee was required as the maximum aggregate offering price remains unchanged from the original May 7, 2026 Form F-1 registration (File No. 333-295328).
▼ Likely negative
· significance 92 · Registration Agent
8-K
CUMBERLAND PHARMACEUTICALS INC
On July 1, 2026, Cumberland closed a $100 million strategic transaction with Apotex Health, divesting its commercial brands and U.S. business. The company retained a clinical-stage pipeline focused on ifetroban, now pursuing FDA approval for DMD cardiomyopathy via NDA submission with rolling review granted. Q3 2026 net income was $77.8M (largely from $81.1M gain on divestiture); cash increased to $80.6M from $11.4M at year-end 2025.
▲ Likely positive
· significance 92 · 8-K Agent
F-1
GrowHub Ltd
GrowHub (Cayman Islands, $1M assets) agreed July 14, 2026 to acquire EnChem America (electrolyte manufacturer, valued at minimum $400M) via reverse merger. GrowHub will issue Class A shares equal to $400M ÷ average closing price over 20 pre-closing trading days (or 85% of fully-diluted post-closing shares, whichever is greater) to EnChem's Korean parent EnChem Co., Ltd. Post-closing, Target Shareholder owns ≥85% (diluting existing GrowHub shareholders to ≤15%). Concurrent best-efforts public offering of up to 2,006,961 Class A shares at assumed $4.31/share; no minimum proceeds required; offering closes only if Merger and Nasdaq approval occur by December 2, 2026. Reverse stock split (1-for-10) effective December 2, 2026.
▼ Likely negative
· significance 92 · Registration Agent
10-Q
UPEXI, INC.
Upexi, Inc. executed a Master Loan Agreement with BitGo Prime, LLC (dated May 22, 2025) for $57,295,723.30 USD, documented in this October 2026 rerate confirmation. The loan is a 30-day evergreen facility at 7.5% annual fee, secured by 200% collateral in Solana (SOL) tokens and USDC held at BitGo Trust Company. Borrower can withdraw unlocked SOL; lender has first priority security interest and broad enforcement powers including asset liquidation at 115% collateral level.
▼ Likely negative
· significance 92 · Periodic Agent
8-K
NEXTNRG, INC.
NEXTNRG, Inc. received a Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard on November 9, 2026, with a transfer of listing. The filing provides no specific details regarding which listing standards were not met, the counterparty exchange, remediation timeline, or financial impact. This represents a critical corporate development for a ~$92.3M market-cap company.
▼ Likely negative
· significance 88 · 8-K Agent
8-K
SUNation Energy, Inc.
Suniva, which is merging with SUNation Energy (SUNE, $9.7M market cap), announced construction of a 4.5 GW solar cell manufacturing facility in Laurens County, South Carolina, expected to cost ~$600 million and increase total U.S. capacity from 1 GW to 5.5 GW. Funding is backed by an $835 million financing closed in September 2026; initial production targeted for late 2027 with full ramp in 2028. The project is expected to create ~560 jobs and is supported by long-term offtake agreements covering majority of planned production through 2030.
▲ Likely positive
· significance 78 · 8-K Agent
8-K
Freenome, Inc.
Freenome completed IPO on July 21, 2026, raising ~$310M gross proceeds, and received FDA approval for SimpleScreen CRC colorectal cancer test on July 24, 2026. Q3 2026 revenue surged to $183.5M (vs. $1.0M in Q3 2025), driven by $182.5M license/collaboration revenue from Abbott (assumed Exact Sciences agreement); $100M milestone payment triggered by FDA approval. Company holds $430M in cash/securities as of Sept 30, 2026; converted ~$50.5M Abbott convertible note into 3.4M shares at $15/share and ~$6.4M Roche convertible note into 6.4M shares at $12/share upon July business combination close.
▲ Likely positive
· significance 78 · 8-K Agent
8-K
INOVIO PHARMACEUTICALS, INC.
Inovio received accelerated FDA approval on October 30, 2026 for VOCERYQ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd), the first FDA-approved DNA medicine, for reducing surgery frequency in RRP patients. The company completed a public offering raising $80.5M net proceeds in November 2026 to support commercialization. VOCERYQ will ship in ~60 days and achieve full commercial launch in Q1 2027; Inovio projects cash runway into late Q4 2027 including the offering proceeds and an estimated $21M Q4 2026 burn rate.
▲ Likely positive
· significance 78 · 8-K Agent
8-K
GEN Restaurant Group, Inc.
GEN Restaurant Group signed a binding letter of intent with Chubby Group, Inc. to sell its 47 U.S. GEN Korean BBQ restaurants in a transaction valued at up to $100 million, with definitive agreements under negotiation. GEN retains its CPG business, brand, and Cerritos flagship restaurant. The deal is expected to eliminate GEN's $26.8M debt, reduce operating lease liabilities, and add a secured note receivable, with restaurants transitioning in four phases over 12 months. Q3 2026 CPG revenue reached $4.7M (vs. $0M prior year); company targets $40M CPG run rate and positive net income by end of 2027.
▲ Likely positive
· significance 78 · 8-K Agent
10-Q
TELA Bio, Inc.
Heather Getz hired as CEO effective August 3, 2026, with $650K base salary, $650K target bonus, and 2.87M share options/RSUs. Same day, founder/President Antony Koblish (Oct 2019 hire) terminated without cause—12-month severance, equity acceleration. Roberto Cuca (COO/CFO, Aug 2021 hire) terminated August 31, 2026 without cause—9-month severance, equity acceleration. September 28, 2026: lender Perceptive Credit Holdings V waived minimum revenue covenant ($80.8M and $86.3M for Q3 and Q4 2026 TTM periods), signaling revenue miss.
▼ Likely negative
· significance 78 · Periodic Agent
8-K
AIR INDUSTRIES GROUP
Air Industries amended its loan agreement with Santander Bank (successor to Webster/Sterling National) on November 9, 2026, extending the maturity date from an earlier date to April 30, 2027, and paying a $50,000 amendment fee with an additional $50,000 fee due at maturity (plus an earlier $150,000 fee from February 2026 due at maturity, totaling $200,000 at April 2027 maturity). Simultaneously, the company extended maturity of related-party convertible subordinated notes held by Michael Taglich ($2.42M principal) and Robert Taglich ($2.45M principal) from December 1, 2026 to May 1, 2027, with automatic 2% principal increases and substantial interest rate resets (to 12.5% minimum or SOFR+8.5%) if a planned merger with Tenax Aerospace does not close by November 30, 2026.
▼ Likely negative
· significance 78 · 8-K Agent
8-K
Swarmer, Inc
Swarmer signed a definitive agreement on September 9, 2026, to acquire Ratel Robotics (Ukrainian UGV manufacturer). Ratel generated $42.1M revenue in 9M 2026 ($32.5M Q3), with $65.1M backlog and projected Q4 2026 revenue of $35M–$40M at 13%–17% operating margins. The acquisition closed in November 2026; Swarmer also announced pending IP acquisition from Vataga Drone and 20% equity stake in Vectus Air Defense with MOU for air defense systems.
▲ Likely positive
· significance 78 · 8-K Agent
8-K
CENTERSPACE
Independence Realty Trust (IRT) and Centerspace shareholders approved their merger on November 10, 2026. Centerspace shareholders will receive 3.800 IRT shares per Centerspace share owned. IRT received 88.1% stockholder approval; Centerspace received 99.6% approval (80.4% of outstanding shares). Closing is subject to remaining conditions and lender consents, with a deadline of June 30, 2027.
— Neutral
· significance 78 · 8-K Agent
8-K
URBAN ONE, INC.
Urban One reported Q3 2026 net revenue of $88.0M (down 5% YoY from $92.7M), with a net loss of $119.2M or $(26.39) per share versus $(0.64) prior year. The company took a $128.9M impairment charge ($62.5M on radio licenses, $25.4M on Radio Broadcasting unit, $40.9M on Cable TV unit). Adjusted EBITDA fell to $12.3M from $14.2M. Balance sheet shows total stockholders' equity of $(102.9)M (negative) as of Sept 30, 2026 versus $24.6M positive at year-end 2025. The company acquired Service Broadcasting (Dallas stations KKDA/KRNB) for $22.0M on July 17, 2026, and sold KZMJ for $6.0M, recognizing a $3.2M gain.
▼ Likely negative
· significance 78 · 8-K Agent
8-K
KULR Technology Group, Inc.
KULR Technology Group filed a Delaware Chancery Court petition seeking validation of numerous corporate actions with technical defects, including: (1) a name change (April 2016, no board approval record); (2) authorized common stock increase from 100M to 500M shares (December 2018, improper stockholder approval); (3) Series A Preferred Stock designation (June 2017) and two issuances to CEO Michael Mo of 730,000 shares (January 26, 2024) and 270,000 shares (January 16, 2025)—increasing Mo's voting power to ~45% then ~33%—with defects in written consent procedures; (4) 8-to-1 reverse stock split (June 20, 2025) that raised Mo's voting power to ~71%; and (5) board expansion and director appointments (June 5, 2025). The company cannot ratify under standard DGCL Section 204 because it cannot track valid vs. putative shares in public float. All acts were done in good faith and treated as valid for years; disinterested directors approved major actions.
▼ Likely negative
· significance 78 · 8-K Agent
SCHEDULE 13D
Chemomab Therapeutics Ltd.
Scipher Medicine Corporation entered into a Convertible Note Purchase and Investment Obligation Agreement (March 5, 2026) with major VCs including Khosla Ventures, Northpond Capital, Blue Owl Healthcare, and others to raise $5.87M+ in convertible notes and commit to $23.49M+ in equity investment upon closing of a Strategic Transaction (reverse merger with Chemomab Therapeutics Ltd., now called Snowdrift Parent). The agreement was amended three times (June 23, July 17, October 29, 2026) extending deadlines to March 31, 2027, authorizing additional July and October 2026 note closings, and allowing investors to satisfy obligations via Chemomab's ATM program. On November 3, 2026, Chemomab consented to Scipher issuing up to $1.1M additional bridge notes to fund Chemomab's pre-closing financing needs.
— Neutral
· significance 78 · Ownership Agent
8-K
CYABRA, INC.
On November 9, 2026, Cyabra, Inc. executed a secured promissory note with Alpha Capital Anstalt for up to $1,500,000 in tranches. The first tranche of $650,000 was funded immediately. The loan carries 10% annual interest (rising to 18% on default), matures January 15, 2027 (extendable to December 31, 2028 at lender's option), and is secured by a first-priority lien on virtually all company assets—accounts, inventory, IP (patents, trademarks, copyrights), subsidiary equity, and books/records—except assets restricted by the Israeli Innovation Authority. The agreement grants the lender broad enforcement powers and attorney-in-fact rights after default.
▼ Likely negative
· significance 77 · 8-K Agent
8-K
WESCO INTERNATIONAL INC
Wesco presented its integrated 'One Wesco' data center strategy at an investor event on November 10, 2026. Data center sales have grown ~300% since Q1 2024 to approximately $6 billion TTM (trailing twelve months through September 30, 2026), now representing ~23% of total company sales (up from ~10% in 2023). The company positions itself as a full Power-to-Compute lifecycle provider across three business units: Utility & Broadband Solutions (UBS, $5.7B sales, provides power/site readiness), Electrical & Electronic Solutions (EES, $9.8B sales, provides gray-space infrastructure), and Communications & Security Solutions (CSS, $10.5B sales, provides white-space connectivity). Specific wins noted include a $1B+ multiyear grid services award and a $1B+ backlog with an MTDC customer; one case study showed revenue scaling from $15M (2024) to $100M+ run rate (2026). No share count, debt figures, or strategic announcements were disclosed.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
Lipocine Inc.
Lipocine dosed the first participant in BLOOM, a Phase 3 placebo-controlled study of LPCN 1154 (oral brexanolone) for postpartum depression, enrolling ~120 participants. The 48-hour at-home oral treatment study incorporates FDA feedback and learnings from a prior failed Phase 3 trial, with topline results expected in H2 2027. FDA confirmed the NDA submission package is complete except for a single positive, well-controlled Phase 3 trial, which BLOOM is designed to provide.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
Black Diamond Therapeutics, Inc.
Black Diamond reported updated Phase 2 results for silevertinib in EGFR-NCM NSCLC: 86% CNS-ORR in 16 patients with untreated brain metastases (7 evaluable by RANO-BM), 15.0-month mPFS in 43-patient ITT cohort, 60% ORR. FDA End-of-Phase 2 meeting (Oct 1, 2026) supported pivotal Phase 3 development targeting ~300 patients, planned Q2 2027 initiation, with potential accelerated approval on CNS-ORR and full approval on PFS. Company has $102.0M cash (down from $128.7M at Dec 31, 2025), runway to H2 2028.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
Sono Group N.V.
Sono Group sold its solar business (May 4, 2026) and now operates as a pure Bitcoin treasury company. Q3 2026 net income was $0.6M ($0.32/share basic) vs. $1.4M loss in Q3 2025, driven by $1.5M fair-value Bitcoin gain and $0.2M covered-call premium, offset by $1.0M loss on in-the-money calls. As of Sept 30, 2026, Sono held 53.40 Bitcoin (fair value $4.4M, pledged to Blockchain.com). On Aug 31, 2026, Sports One investors purchased 283,500 ordinary shares (19.9% stake) at market price in registered direct offering; parties signed non-binding LOI for business combination with Sports One to operate sports intelligence and acquire minority sports team interests. Delaware redomiciliation shareholder vote scheduled Dec 11, 2026. Critical: company disclosed substantial doubt about going concern; $5.05M convertible debentures mature Jan–Apr 2027; only $0.5M cash on hand.
▼ Likely negative
· significance 72 · 8-K Agent
10-Q
Meridian Holdings Inc./NV
Meridian Gaming Limited (Malta-incorporated subsidiary of Meridian Holdings) amended its loan agreement with lender Igor Salindrija on 13 October 2026, effective 1 September 2026. Outstanding principal of EUR 550,000 (approx. $594K at typical rates) plus EUR 22,482.43 unpaid prior interest is rescheduled for repayment by 1 March 2027 in five instalments (EUR 100K, 100K, 100K, 100K, 150K due Nov 2026–Mar 2027); total interest payable EUR 35,878.32. This is the third amendment since the original EUR 2,000,000 loan dated 1 April 2024.
▼ Likely negative
· significance 72 · Periodic Agent
8-K
Venture Global, Inc.
Venture Global reported Q3 2026 revenue of $4.8B (+43% YoY) and net income of $2.5B (+493% YoY). The company commenced commercial operations at Plaquemines Phase 1 on October 31, 2026, after 53 months from FID. Full-year 2026 Consolidated Adjusted EBITDA guidance was raised to $10.0–$10.3B from $8.7–$9.1B. The company also announced frame agreements with GE Vernova and Baker Hughes for up to 16 new 720 MW power units to support a new AI utility/data center business, and executed 2.0 MTPA of new 20-year LNG offtake agreements (ConocoPhillips 1.0 MTPA, China Gas 0.5 MTPA, existing customer +0.5 MTPA).
▲ Likely positive
· significance 72 · 8-K Agent
8-K
HARVARD BIOSCIENCE INC
In December 2025, Harvard Bioscience refinanced ~$40M in debt (Term Loans A, B, C from BroadOak Capital), extending maturity to December 2029 with blended interest rates ranging 12.50%–12.80% (first 2 years), achieving $3M in annual cash savings. Separately, Project Viking—announced Q1 2026—consolidates U.S. manufacturing from Holliston, MA to Minneapolis over 15 months (completion Q1 2027), targeting $3M adj. EBITDA improvement in 2027 and $4M/year thereafter. 3Q26 revenue was $22.2M (+8% YoY); FY26 guidance lowered to 3–5% growth and (1%)–4% adj. EBITDA growth (vs. prior 6–10%). BroadOak received warrants for 200K shares at $5/share and board nomination rights.
— Neutral
· significance 72 · 8-K Agent
8-K
D-Wave Quantum Inc.
D-Wave executed a definitive agreement with the U.S. Department of Commerce for up to $100 million in CHIPS and Science Act funding (subject to milestones) to develop a 100,000-qubit annealing system and 10,000-qubit gate-model system. Nine-month 2026 bookings reached $37.4 million (611% YoY increase); Q3 revenue $4.5M (21% YoY); RPO $38.3M (1,221% YoY). The company acquired Quantum Circuits in January 2026 and expanded partnerships with NTT DOCOMO, CGI, LG CNS, and SkyWater.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
Scholar Rock Holding Corp
Scholar Rock received FDA approval for ISEMBYLD (apitegromab-mstn) on September 11, 2026, for SMA in patients ≥2 years on SMN2-targeted therapy. Q3 2026 product revenue was $0.6M from initial shipments; early launch shows broad prescriber and patient demand across geographies and patient backgrounds. In November 2026, Scholar Rock signed a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher for $205M (non-dilutive capital). Cash position: $413.6M as of September 30, 2026. EMA resubmitted MAA validated in October 2026 (CHMP opinion expected H1 2027); Japan JNDA submitted and accepted under priority review. Net loss Q3 2026: $107.2M (vs. $102.2M Q3 2025); no material change in R&D ($54.1M) or SG&A ($52.5M) spend.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
KUSTOM ENTERTAINMENT, INC.
Kustom Entertainment completed sale of legacy video solutions business to Cycurion Inc. on August 3, 2026, receiving a $4.25M secured promissory note (7%) and $600K Series H preferred stock. Q3 2026 continuing operations revenue grew 57% to $2.7M; net income (including $5M gain on divestiture) reached $2.3M. Stockholders' equity more than tripled to $7.9M and total liabilities fell $9.3M since year-end 2025. Company is now pursuing acquisition of TFL LLC (ticketing technology), with stockholder approval obtained October 5, 2026 and outside closing date extended to December 18, 2026.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
Arbutus Biopharma Corp
Arbutus received $178.4M (its share) from a $950M noncontingent Moderna settlement payment in July 2026, with an additional $1.3B contingent on an appellate ruling. The company returned $230M to shareholders via tender offer in early October 2026, repurchasing 46M shares (23% of outstanding) at $5.00/share. Cash position stood at $337.5M as of September 30, 2026. Additionally, the FDA lifted a clinical hold on AB-101 (oral PD-L1 inhibitor), and Arbutus expanded patent litigation against Pfizer/BioNTech with new lawsuits in Japan and amended Canadian lawsuit.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
Ambiq Micro, Inc.
Ambiq reported Q3 2026 net sales of $38.1M (up 110% YoY from $18.2M), with GAAP gross profit of $17.8M (up 132% YoY) and gross margin expanding 440 bps to 46.7%. Active customer base grew ~50% YoY; 7 customers now generate >$1M quarterly revenue vs. 3 in prior year. Company raised Q4 2026 guidance to $43.5M–$44.5M in net sales. Cash position strengthened to $363.5M (Sept 30, 2026) from $140.3M (Dec 31, 2025) via $245.5M follow-on equity offering completed in Q3. Despite strong top-line growth, GAAP net loss in Q3 was $(7.1)M; non-GAAP net loss improved to $(1.2)M.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
AST SpaceMobile, Inc.
AST SpaceMobile and Rakuten Group established Rakuten AST, Inc. (51% Rakuten / 49% AST) on November 6, 2026, to build a direct-to-device satellite network in Japan. The joint venture received ~USD 1 billion (148 billion yen) in funding from Japan's Ministry of Internal Affairs and Communications over three years to deploy mid-band LEO satellites. AST will supply satellites; commercial operations are targeted for end of Q1 2029, with potential global service expansion outside Japan subject to regulatory approval.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
PepGen Inc.
PepGen reported positive Phase 2 topline data from the 10 mg/kg dose cohort of FREEDOM2-DM1 evaluating PGN-EDODM1 in myotonic dystrophy type 1 (DM1). Key results: mean splicing correction of 46.5% (highest reported in a multiple-dose study), with 5 of 6 patients showing >20% improvement and 4 of 6 exceeding 50% correction; functional improvements across video Hand Opening Time (52.7% improvement, 3.9 seconds), hand grip strength (16.2% improvement), Timed Up and Go (8.5% improvement), and 10-Meter Walk/Run Test (6.8% improvement); favorable safety profile with no serious/severe adverse events, no dose-limiting toxicities, or discontinuations. The 12.5 mg/kg cohort is fully enrolled with results expected H1 2027. Company has $104.8M cash (sufficient runway into 2028) with 69.3M shares outstanding as of September 30, 2026. Q3 2026 net loss was $19.4M ($0.28 per share).
▲ Likely positive
· significance 72 · 8-K Agent
8-K
Coya Therapeutics, Inc.
Coya completed enrollment of 137 participants (vs. 120 planned) in its Phase 2/3 ALSTARS trial of COYA 302 for ALS treatment. The company holds $35.8M cash as of Sept 30, 2026, sufficient to fund operations past the Q2 2027 topline readout into H2 2027. Q3 2026 net loss was $10.6M (vs. $2.1M in Q3 2025); R&D expenses rose $5.7M driven by clinical trial advancement.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
Tyra Biosciences, Inc.
Tyra Biosciences completed a $400M underwritten public offering in September 2026 (led by RA Capital Management) and reported initial Phase 2 SURF302 results for oral dabogratinib in FGFR3-altered low-grade IR NMIBC: 79% overall response rate and 64% complete response rate at 60 mg QD (n=14), with 100% ORR and 75% CR among single-lesion patients (n=8); no Grade 3 treatment-related adverse events at this dose. Cash position is now $700.5M as of September 30, 2026, funding operations through 2030. Q3 2026 net loss was $51.1M vs. $29.9M in Q3 2025; R&D expenses increased 69% YoY to $43.1M.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
Jerash Holdings
For Q2 FY2027 (ended Sept 30, 2026), Jerash reported revenue of $50.3M (vs. $42.0M prior year), gross profit of $9.1M (+45.4% YoY), and net income of $2.2M (+360% YoY). Gross margin expanded 320 basis points to 18.2% driven by higher U.S. customer shipments, automation gains, advance raw material purchases, and a Jordanian tax concession reducing corporate rate from 20% to 10% effective Oct 2025. For H1 FY2027, revenue reached $100.5M (+23.2%), net income $3.8M (+378% YoY). The company projects Q3 revenue of $49–51M (+17–22% YoY) with 16–17% gross margin. Capacity expansion (15–20%) expected by Sept 2027; facilities fully booked through June 2027. Dividend approved: $0.05/share on Nov 23, 2026.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
Turn Therapeutics Inc.
Turn Therapeutics, a $17M-asset biotech, disclosed Phase 2a interim results for GX-03 (IL-36/IL-31 inhibitor topical) in moderate-to-severe atopic dermatitis. In an enriched subgroup (n=25, baseline pruritus NRS≥7), GX-03 achieved 61.5% Week 4 vIGA success vs 8.3% vehicle (Δ53.2%, p~0.012). Phase 2b expansion (~120–136 patients) is enrolling with topline expected Q1 2027; Phase 3 planned mid-2027. Company also plans Phase 3 for onychomycosis (Q2 2027 initiation) and Phase 2a for hidradenitis suppurativa (Q1 2027). Cash runway extends to Q3 2027 (~$10.4M as of Sept 30, 2026); $1M/quarter burn.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
Dominari Holdings Inc.
Dominari reported Q3 2026 revenue of $16.4M (down 69% YoY from $52.4M), driven by lower underwriting ($25.7M decline), carried interest ($3.7M lower), and commissions ($4.3M lower). Operating expenses fell $34.6M (65% reduction) to $18.3M, shrinking the operating loss to $1.9M from $0.4M prior year. However, cash declined from $34.0M (Dec 2025) to $24.0M (Sept 2026), stockholders' equity fell from $69.4M to $22.4M, and YTD net loss was $64.7M. The company initiated a $5M share repurchase, completing $3.4M of buybacks (1.9M shares) and raised $3.3M via warrant inducement.
▼ Likely negative
· significance 72 · 8-K Agent
8-K
MAXCYTE, INC.
MaxCyte (MXCT, $231M market cap) is acquiring Ohio Intermediate LLC and related entities (collectively 'Acquired Companies,' primarily BioP) from Ohio TopCo LP and Arcline Capital Partners for: (1) Estimated Closing Cash Payment (subject to working capital adjustment), (2) Stock Consideration (unspecified share count, <20% of MaxCyte), and (3) $20M in Deferred Payments ($10M each in 2028 and 2029). Transaction dated November 9, 2026, with Closing expected ~120 days thereafter pending HSR clearance. Deal includes $10M-$20M earnout-like deferred components and assumes Acquired Companies' indebtedness and transaction expenses.
— Neutral
· significance 72 · 8-K Agent
8-K
Veradermics, Inc
Veradermics announced positive topline results from Phase 3 Study 304 and 12-month data from Phase 2/3 Study 302 for VDPHL01 (extended-release minoxidil) in male pattern hair loss, with efficacy endpoints met (36.4–43.9 hairs/cm² increase at 6–12 months, 55.7–89.1% visible improvement rates) and favorable safety profiles. Female Phase 2 Study 207 also showed positive results; Study 306 (female Phase 2/3) enrollment complete with topline data expected 1H27. Cash position of $798.4M as of September 30, 2026, is expected to fund operations through 2030 and multiple Phase 3 readouts. Q3 2026 net loss was $21.0M (vs. $20.1M in Q3 2025); R&D expenses decreased $2.0M YoY to $16.1M, while G&A expenses increased $10.5M to $12.7M, driven by commercial readiness costs and stock-based compensation.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
Safe Pro Group Inc.
Safe Pro Group Inc. received a $2.5 million U.S. Government prime contract from the U.S. Army for its super intelligence threat-detection software to run on Anduril Industries' Ghost-X drone platform, enabling real-time identification of 150+ types of explosive threats (landmines, cluster munitions, FPV drones) for Abrams Tank protection. The contract represents Safe Pro's first prime contract award and integrates its Ground Truth Air software into Anduril's drone for tactical edge processing and Army network integration (ATAK, Lattice).
▲ Likely positive
· significance 72 · 8-K Agent
8-K
Allison Transmission Holdings Inc
Allison Transmission acquired Dana Incorporated's Off-Highway Drive Motion Systems business (now 'Allison Off-Highway' or AOH), effective 2026. YTD nine-month 2026 results show combined entity with $4.51B net sales, $1.17B adjusted EBITDA (25.9% margin), and $662M adjusted free cash flow. AOH contributed ~$2.0B annualized 2026 net sales with $285M adjusted EBITDA (14.0% margin); full-year 2026 guidance: $6.03B net sales, $1.56B adjusted EBITDA (25.8% margin). The acquisition adds manufacturing footprint (30 facilities), ~11,000 employees, and expands portfolio into transmissions, axles, gearboxes, and electrified propulsion across construction, agriculture, mining, and industrial end markets.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
CAPRICOR THERAPEUTICS, INC.
Capricor submitted a major BLA amendment for Deramiocel (CAP-1002) for DMD, adding two-year HOPE-3 open-label extension data showing 76% slower upper limb decline in patients who switched from placebo to treatment, with a refined indication focused on upper limb impairment in patients 9 years old. The FDA extended review by three months to November 22, 2026. Cash position stands at $198.5M as of September 30, 2026, down from $318.1M at year-end 2025; nine-month 2026 net loss was $117.3M versus $74.9M in 2026, with operating expenses rising 57% year-over-year to $124.4M driven by pre-commercial activities and manufacturing scale-up.
▲ Likely positive
· significance 72 · 8-K Agent
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.